Irritable Bowel Syndrome Treatment Market Size, Share & Report

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Region, And Segment Forecasts, 2019 - 2026

  • Published Date: Jul 2019
  • Report ID: GVR-3-68038-319-5
  • Number of Pages: 185
  • Format: Electronic (PDF)
  • Historical Data: 2014 - 2017

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Market Segmentation & Scope
                    1.2. Market Definition
                    1.3. Information Procurement
                        1.3.1. Purchased database
                        1.3.2. GVR’s internal database
                        1.3.3. Secondary sources & Third party perspectives
                        1.3.4. Primary research
                    1.4. Information Analysis
                        1.4.1. Data analysis models
                    1.5. Market Formulation & Data Visualization
                    1.6. Data Validation & Publishing
Chapter 2. Executive Summary
                    2.1. Market Outlook
                    2.2. Segment Outlook
                    2.3. Competitive Insights
Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends & Scope
                    3.1. Irritable Bowel Syndrome Treatment Market Lineage outlook
                        3.1.1. IBD market outlook
                    3.2. Penetration & Growth Prospect Mapping
                    3.3. Regulatory Framework
                        3.3.1. Reimbursement framework
                        3.3.2. Standards & compliances
                    3.4. Market Dynamics
                        3.4.1. Market driver analysis
                            3.4.1.1. Increase in geriatric population
                            3.4.1.2. Increasing prevalence of IBS
                        3.4.2. Market restraint analysis
                            3.4.2.1. Less awareness about the symptoms
                    3.5. Irritable Bowel Syndrome Treatment Market Analysis Tools
                        3.5.1. Industry analysis - Porter’s
                            3.5.1.1. Supplier power (Moderate due to requirement of high-quality raw materials)
                            3.5.1.2. Buyer power (Low due to limited number of established providers)
                            3.5.1.3. Substitution threat (Moderate due to high prices)
                            3.5.1.4. New entrants’ threat (High as the market is underserved)
                            3.5.1.5. Competitive rivalry (Moderate due to presence of few key players)
                        3.5.2. PESTEL analysis
                            3.5.2.1. Political landscape
                            3.5.2.2. Environmental landscape
                            3.5.2.3. Social landscape
                            3.5.2.4. Technology landscape
                            3.5.2.5. Legal landscape
                        3.5.3. Major deals & strategic alliances analysis
                            3.5.3.1. Joint ventures
                            3.5.3.2. Mergers & acquisitions
                            3.5.3.3. Licensing & partnership
                            3.5.3.4. Technology collaborations
                            3.5.3.5. Strategic divestments
Chapter 4. Irritable Bowel Syndrome Treatment Market - Competitive Analysis
                    4.1. Recent Developments & Impact Analysis, by Key Market Participants
                    4.2. Company/Competition Categorization (Key Innovators, Market Leaders, Emerging Players)
                    4.3. Vendor Landscape
                        4.3.1. List of key distributors and channel partners
                        4.3.2. Key company market share analysis, 2018
                    4.4. Public Companies
                        4.4.1. Company market position analysis (Revenue, geographic presence, product portfolio, key serviceable industries, key alliances)
                        4.4.2. Company market share
                        4.4.3. Competitive dashboard analysis
                        4.4.4. Market differentiators
                        4.4.5. Synergy analysis: Major deals & strategic alliances
                    4.5. Private Companies
                        4.5.1. List of key emerging companies
                        4.5.2. Regional network map
                        4.5.3. Company market position analysis (geographic presence, product portfolio, key alliance, industry experience)
Chapter 5. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis
                    5.1. Definitions & Scope
                    5.2. Type Market Share Analysis, 2018 & 2026
                    5.3. Irritable Bowel Syndrome Treatment Market, by Type, 2014 to 2026
                    5.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                        5.4.1. IBS-C
                            5.4.1.1 IBS-C market, 2014 - 2026 (USD Million)
                            5.4.1.2 Linzess/Constella
                                5.4.1.2.1 Linzess/Constella market, 2014 - 2026 (USD Million)
                            5.4.1.3 Amitiza
                                5.4.1.3.1 Amitiza market, 2014 - 2026 (USD Million)
                            5.4.1.4 Others
                                5.4.1.4.1 Others market, 2014 - 2026 (USD Million)
                        5.4.2. IBS-D
                            5.4.2.1 IBS-D market, 2014 - 2026 (USD Million)
                            5.4.2.2 Xifaxan
                                5.4.2.2.1 Xifaxan market, 2014 - 2026 (USD Million)
                            5.4.2.3 Viberzi
                                5.4.2.3.1 Viberzi market, 2014 - 2026 (USD Million)
                            5.4.2.4 Others
                                5.4.2.4.1 Others market, 2014 - 2026 (USD Million)
Chapter 6. Irritable Bowel Syndrome Treatment Market: Product Estimates & Trend Analysis
                    6.1. Definitions & Scope
                    6.2. Product Market Share Analysis, 2018 & 2026
                    6.3. Irritable Bowel Syndrome Treatment Market, by Product, 2014 to 2026
                    6.4. Market Size & Forecasts and Trend Analyses, 2014 to 2026 for the following,
                        6.4.1. Xifaxan
                            6.4.1.1 Xifaxan market, 2014 - 2026 (USD Million)
                        6.4.2. Linzess/Constella
                            6.4.2.1 Linzess/Constella market, 2014 - 2026 (USD Million)
                        6.4.3. Viberzi
                            6.4.3.1 Viberzi market, 2014 - 2026 (USD Million)
                        6.4.4. Amitiza
                            6.4.4.1 Amitiza market, 2014 - 2026 (USD Million)
                        6.4.5. Others
                            6.4.5.1 Others market, 2014 - 2026 (USD Million)
Chapter 7 Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis, by Product, Test Location, Technology, & Application
                    7.1 Irritable Bowel Syndrome Treatment Market: Regional Movement Analysis, 2018 & 2026
                    7.2 Irritable Bowel Syndrome Treatment Market: Leading Players, 2018:
                        7.2.1. North America
                        7.2.2. Europe
                        7.2.3. Asia Pacific
                        7.2.4. Latin America
                        7.2.5. Middle East & Africa
                    7.3 SWOT Analysis, by Factor (Political & Legal, Economic And Technological)
                        7.3.1. North America
                        7.3.2. Europe
                        7.3.3. Asia Pacific
                        7.3.4. Latin America
                        7.3.5. Middle East & Africa
                    7.4 North America
                        7.4.1 North America market, 2014 - 2026 (USD Million)
                        7.4.2 U.S.
                            7.4.2.1 U.S. market, 2014 - 2026 (USD Million)
                        7.4.3 Canada
                            7.4.3.1 Canada market, 2014 - 2026 (USD Million)
                    7.5. Europe
                        7.5.1 Europe market, 2014 - 2026 (USD Million)
                        7.5.2 U.K.
                            7.5.2.1 U.K. market, 2014 - 2026 (USD Million)
                        7.5.3 Germany
                            7.5.3.1 Germany market, 2014 - 2026 (USD Million)
                        7.5.4 Italy
                            7.5.4.1 Italy market, 2014 - 2026 (USD Million)
                        7.5.5 Spain
                            7.5.5.1 Spain market, 2014 - 2026 (USD Million)
                    7.6 Asia Pacific
                        7.6.1 Asia Pacific market, 2014 - 2026 (USD Million)
                        7.6.2 Japan
                            7.6.2.1 Japan market, 2014 - 2026 (USD Million)
                        7.6.3 China
                            7.6.3.1 China market, 2014 - 2026 (USD Million)
                    7.7 Latin America
                        7.7.1 Latin America market, 2014 - 2026 (USD Million)
                        7.7.2 Brazil
                            7.7.2.1 Brazil market, 2014 - 2026 (USD Million)
                        7.7.3 Mexico
                            7.7.3.1 Mexico market, 2014 - 2026 (USD Million)
                    7.8 MEA
                        7.8.1 MEA market, 2014 - 2026 (USD Million)
                        7.8.2 South Africa
                            7.8.2.1 South Africa market, 2014 - 2026 (USD Million)
Chapter 8 Competitive Landscape
                    8.1 Strategy Framework
                    8.2 Heat Map Analysis of Private Companies
                        8.2.1 Company size
                        8.2.2 Distribution network
                        8.2.3 Product portfolio
                        8.2.4 Segment coverage
                        8.2.5 Geographic presence
                        8.2.6 Collaborations
                        8.2.7 Conclusion
                    8.3 Ironwood Pharmaceuticals, Inc.
                        8.3.1 Company overview
                        8.3.2 Financial performance
                        8.3.3 Product benchmarking
                        8.3.4 Strategic initiatives
                    8.4 Allergan
                        8.4.1 Company overview
                        8.4.2 Financial performance
                        8.4.3 Product benchmarking
                        8.4.4 Strategic initiatives
                    8.5 Astellas Pharma, Inc.
                        8.5.1 Company overview
                        8.5.2 Financial performance
                        8.5.3 Product benchmarking
                        8.5.4 Strategic initiatives
                    8.6 Takeda Pharmaceutical Company Limited
                        8.6.1 Company overview
                        8.6.2 Financial performance
                        8.6.3 Product benchmarking
                        8.6.4 Strategic initiatives
                    8.7 AstraZeneca
                        8.7.1 Company overview
                        8.7.2 Financial performance
                        8.7.3 Product benchmarking
                        8.7.4 Strategic initiatives
                    8.8 Sebela Pharmaceuticals Inc.
                        8.8.1 Company overview
                        8.8.2 Financial performance
                        8.8.3 Product benchmarking
                        8.8.4 Strategic initiatives
                    8.9 Synergy Pharmaceuticals Inc.
                        8.9.1 Company overview
                        8.9.2 Financial performance
                        8.9.3 Product benchmarking
                        8.9.4 Strategic initiatives
                    8.10 Synthetic Biologics, Inc.
                        8.10.1 Company overview
                        8.10.2 Product benchmarking
                        8.10.3 Strategic initiatives
                    8.11 Bausch Health
                        8.11.1 Company Overview
                        8.11.2 Financial performance
                        8.11.3 Product benchmarking
                        8.11.4 Strategic initiatives
                    8.12 Ardelyx
                        8.12.1 Company overview
                        8.12.2 Financial performance
                        8.12.3 Product benchmarking
                        8.12.4 Strategic initiatives


List of Tables

TABLE 1 Country share estimation
TABLE 2 North America irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 3 North America irritable bowel syndrome treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 4 U.S. irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 5 U.S. irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 6 Canada irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 7 Canada irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 8 Europe irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 9 Europe irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 10 U.K. irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 11 U.K. irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 12 Germany irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 13 Germany irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 14 Italy irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 15 Italy irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 16 Spain irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 17 Spain irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 18 Asia Pacific irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 19 Asia Pacific irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 20 Japan irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 21 Japan irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 22 China irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 23 China irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 24 Latin America irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 25 Latin America irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 26 Brazil irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 27 Brazil irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 28 Mexico irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 29 Mexico irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 30 MEA irritable bowel syndrome treatment market estimates and forecasts, by type, 2014 - 2026 (USD Million)
TABLE 31 MEA irritable bowel syndrome treatment treatment market estimates and forecasts, by product, 2014 - 2026 (USD Million)
TABLE 32 South Africa irritable bowel syndrome treatment treatment market estimates and forecasts, by technology, 2014 - 2026 (USD Million)
TABLE 33 South Africa PCR market estimates and forecasts, by type, 2014 - 2026 (USD Million)


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Market summary, 2018
FIG. 4 Market trends & outlook
FIG. 5 Market segmentation & scope
FIG. 6 Market driver relevance analysis (Current & future impact)
FIG. 7 Market restrain relevance analysis (Current & future impact)
FIG. 8 Penetration & growth prospect mapping
FIG. 9 SWOT analysis, by factor (political & legal, economic and technological)
FIG. 10 Porter’s five forces analysis
FIG. 11 Irritable bowel syndrome treatment market type outlook key takeaways
FIG. 12 Irritable bowel syndrome treatment market: Type movement analysis
FIG. 13 Global IBS-C market, 2014 - 2026 (USD Million)
FIG. 14 Global IBS-D market, 2014 - 2026 (USD Million)
FIG. 15 Irritable bowel syndrome treatment market product outlook: Key takeaways
FIG. 16 Irritable bowel syndrome treatment market: Product movement analysis
FIG. 17 Global Xifaxan market, 2014 - 2026 (USD Million)
FIG. 18 Global Linzess/Constella market, 2014 - 2026 (USD Million)
FIG. 19 Global Amitiza market, 2014 - 2026 (USD Million)
FIG. 20 Global Viberzi market, 2014 - 2026 (USD Million)
FIG. 21 Global others market, 2014 - 2026 (USD Million)
FIG. 22 Regional market place: Key takeaways, 2018
FIG. 23 Regional outlook, 2018 & 2026
FIG. 24 North America irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 25 U.S. irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 26 Canada irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 27 Europe irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 28 U.K. irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 29 Germany irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 30 Spain irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 31 Italy irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 32 Asia Pacific irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 33 Japan irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 34 China irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 35 Latin America irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 36 Brazil irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 37 Mexico irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 38 MEA irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 39 South Africa irritable bowel syndrome treatment market, 2014 - 2026 (USD Million)
FIG. 40 Strategy framework
FIG. 41 Participant categorization

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.